Sanofi Withdraws Applications for Blood-Clot Drug Mulsevo

Sanofi withdrew its marketing authorization requests for the Mulsevo drug to prevent blood clots in chemotherapy patients, a setback for efforts by France’s biggest drugmaker to bring new medicines to patients.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.